Search clinical trials for: Post-polycythemia vera myelofbrosis (Post PV-PMF)

Total 10379 results

Kartos Therapeutics, Inc.

Recruiting

KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment (BOREAS)

Primary Myelofibrosis (PMF) | Post-Polycythemia Vera MF (Post-PV-MF) | Post-Essential Thrombocythemia MF (Post-ET-MF)

United States, Korea, Republic of, Germany, Australia, Hungary, France, Spain, Italy, Taiwan, Thailand, Brazil, Poland, Turkey, Israel, Portugal, Romania, Argentina, Bulgaria, Canada, Croatia, Czechia, Lithuania, Mexico, Philippines, United... and more
University of Ulm

Active, not recruiting

Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary MF (POMINC)

Primary Myelofibrosis | Secondary Myelofibrosis | Post-PV MF | PMF | SMF | Post-ET MF

Germany
University of Edinburgh
Accord Clinical Research

Recruiting

Fatigue in Lupus Intervention Programmes (FLIP) (FLIP)

Systemic Lupus Erythematosus

United Kingdom
Sierra Oncology, Inc.

Completed

Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)

Primary Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | Post-Essential Thrombocythemia Myelofibrosis

United States, Canada, Australia
Sierra Oncology LLC - a GSK company

Completed

Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)

Primary Myelofibrosis (PMF) | Post-polycythemia Vera (Post-PV) Myelofibrosis | Postessential Thrombocythemia (Post-ET) Myelofibrosis

United States, Canada
PV-Nord

Completed

Efficacy and Safety of Pegylated Interferon Alfa in Polycythemia Vera

Polycythemia Vera

France
Samus Therapeutics, Inc.

Terminated

Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib

Primary Myelofibrosis (PMF) | Post-Polycythemia Vera Myelofibrosis (Post-PV MF) | Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)

United States
Memorial Sloan Kettering Cancer Center
Novartis

Terminated

HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET

Myeloproliferative Neoplasms

United States
Sierra Oncology, Inc.

Completed

Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF (Simplify 2)

Primary Myelofibrosis (PMF) | Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) | Post-polycythemia Vera (Post-PV)

United States, Canada, France, Italy, Germany, Spain, Israel, United Kingdom
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Completed

Jaktinib for the Treatment of Ruxolitinib Intolerance of Myelofibrosis

Primary Myelofibrosis (PMF) | Post-polycythemia Vera Myelofibrosis(Post-PV MF) | Post-essential Thrombocythemia Myelofibrosis(Post-ET MF)

China
GlaxoSmithKline

Active, not recruiting

Extended Access of Momelotinib in Adults With Myelofibrosis

Neoplasms | Primary Myelofibrosis (PMF) | Post-polycythemia Vera Myelofibrosis (Post-PV MF) | Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)

United States, Hungary, Israel, Spain, Taiwan, France, Australia, Germany, Belgium, Canada, Singapore, Korea, Republic of, United Kingdom, Denmark, Austria, Romania, Italy, Bulgaria, Poland, Netherlands
Icahn School of Medicine at Mount Sinai
Dompé Farmaceutici S.p.A

Recruiting

Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)

Myelofibrosis (PMF) | Post Essential Thrombocythemia Myelofibrosis (ET-MF) | Post Polycythemia Vera Related Myelofibrosis (PV-MF)

United States
Kartos Therapeutics, Inc.

Recruiting

Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis

Primary Myelofibrosis (PMF) | Post-Polycythemia Vera Myelofibrosis (Post-PV-MF) | Post-Essential Thrombocythemia Myelofibrosis (Post-ET-MF)

United States, Mexico, Bulgaria, Poland, Russian Federation, Belarus, Georgia, South Africa, Ukraine
Staedtisches Klinikum Karlsruhe
Heidelberg University

Completed

PV-Isolation With the Cryoballoon Versus RF:a Randomized Controlled Prospective Non-inferiority Trial (FreezeAF) (FreezeAF)

Atrial Fibrillation

Germany
AstraZeneca
University of Texas; Gustave Roussy, Cancer Campus, Grand Paris; New York City...

Completed

Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases

Primary Myelofibrosis (PMF) | Post-Polycythaemia Vera | Essential Thrombocythaemia Myelofibrosis

United States, France
Celgene
Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation

Completed

A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib (FREEDOM)

Primary Myelofibrosis | Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States, Canada
Marmara University

Completed

Effectiveness of Finger and Forehead Plethysmographic Variability Index Monitoring in Pediatric Patients

PVI

Turkey
Celgene
Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation

Active, not recruiting

An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib (FREEDOM2)

Primary Myelofibrosis | Myelofibrosis | Post-Polycythemia Vera

Australia, Austria, Belgium, China, Czechia, France, Germany, Hungary, Italy, Korea, Republic of, Netherlands, Poland, Russian Federation, Spain, Ireland, United Kingdom
M.D. Anderson Cancer Center
S*BIO

Completed

Study of SB939 in Subjects With Myelofibrosis

Myeloproliferative Disorders

United States
Sierra Oncology, Inc.

Completed

Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)

Primary Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | Post-Essential Thrombocythemia Myelofibrosis

United States, Canada, Australia
Yonsei University

Recruiting

Computed Tomogram Myocardial Thickness Map Guided pulmOnary Vein iSolaTion vs. Empirical Pulmonary Vein Isolation in Cryoballoon Ablation for Paroxysmal Atrial Fibrillation (UTMOST AF II)

Paroxysmal Atrial Fibrillation

Korea, Republic of
Krasnoyarsk Regional Hospital

Unknown

Safety Procedure Pulmonary Artery Denervation in Addition to Pulmonary Vein Isolation Combined With Ganglionated Plexi Ablation in Patients With Persistent Atrial Fibrillation and Pulmonary Hypertension

Pathologic Processes | Heart Diseases | Cardiovascular Diseases | Lung Diseases | Atrial Fibrillation | Arrhythmias, Cardiac | Hypertension, Pulmonary
Protagonist Therapeutics, Inc.

Completed

PTG-300 in Patients With Polycythemia Vera and Elevated Hematocrit (PACIFIC)

Polycythemia Vera

Korea, Republic of, Malaysia
Weill Medical College of Cornell University

Completed

Treatment of Polycythemia Vera With Gleevec

Polycythemia Vera

United States
Meshalkin Research Institute of Pathology of Circulation

Completed

Combined Treatment of Arterial Hypertension and Atrial Fibrillation

Atrial Fibrillation | Arterial Hypertension

Russian Federation, United States, Greece
Deutsches Herzzentrum Muenchen

Unknown

Pulmonary Vein (PV) -Isolation: Arrhythmogenic Vein(s) Versus All Veins (PAVAV)

Atrial Fibrillation

Germany
Silence Therapeutics plc

Recruiting

Study to Assess SLN124 in Patients With Polycythemia Vera (SLN)

Polycythemia Vera

United States, Australia, Malaysia, Bulgaria, Poland
M.D. Anderson Cancer Center
Active Biotech AB

Not yet recruiting

Open Label Phase 2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-Essential Thrombocytosis Myelofibrosis

United States
University of Hawaii
University of Hawaii Cancer Research Center

Terminated

Clinical Study of Noni Extract in Men With Very Low Risk or Low Risk Prostate Cancer

Prostate Cancer

United States
Chengdu Zenitar Biomedical Technology Co., Ltd

Recruiting

Flunotinib Maleate Phase II Intermediate-High Risk Bone Fiber Clinical Trial

MF,PMF,PPV-MF,PET-MF

China
Texas Cardiac Arrhythmia Research Foundation

Completed

Effect of Empirical Left Atrial Appendage Isolation on Long-term Procedure Outcome in Patients With Persistent or Long-standing Persistent Atrial Fibrillation Undergoing Catheter Ablation (BELIEF)

Persistent Atrial Fibrillation

United States
Policlinica Metropolitana

Not yet recruiting

Management of Intraoperative Fluids in Ambulatory Surgery (MIFAS)

Anesthesia, General | Fluid Therapy | Ambulatory Surgical Procedures

Venezuela
Incyte Corporation

Completed

Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)

MPN (Myeloproliferative Neoplasms)

United States
PrimeVax Immuno-Oncology Inc.
Walter Reed Army Institute of Research (WRAIR)

Not yet recruiting

Intratumoral Injection of PV-001-DV Plus DC in Patients With Melanoma

Advanced Melanoma
Cardiovascular Research Society, Greece

Completed

Circumferential Versus Ganglionated Plexi Ablation for Atrial Fibrillation (AF)

Atrial Fibrillation

Russian Federation, Greece
Assiut University

Unknown

Correlation Between (PV-RQOL), The Auditory Perceptual Assessment and Acoustic Analysis of Voice in Dysphonic Children

Dysphonia
Maria Cecilia Hospital

Recruiting

Prospective Evaluation of Biophysical Parameters as Long-term Predictors of Pulmonary Vein Isolation (MERCY)

Atrial Fibrillation

Italy
Novartis Pharmaceuticals

Completed

A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF

Bone Marrow Diseases | Hematologic Diseases | Blood Coagulation Disorders | Hemorrhagic Disorders | Primary Myelofibrosis | Myeloproliferative Disorders | Polycythemia Vera | Thrombocytosis | Essential Thrombocythemia | Blood Platelet Disorders

United Kingdom, Belgium, Canada, France, Australia, Netherlands, Spain, Denmark, Ireland, Italy, Germany
Fondazione Italiana Sindromi Mielodisplastiche-ETS

Completed

Identification of Mechanism in the Erythroid Response in Patients With Myelodysplasia Undergoing Chelation Therapy (BIOFER12)

Myelofibrosis | Aplastic Anemia | Myelodysplasia

Italy
Pathway Medical Technologies Inc.

Completed

The Pathway PVD Study for Percutaneous Peripheral Vascular Interventions

Peripheral Artery Disease
PrimeVax Immuno-Oncology Inc.
Walter Reed Army Institute of Research (WRAIR)

Not yet recruiting

Intratumoral Injection of Dengue Virus-1 #45AZ5 (PV-001-DV) in Patients With Melanoma

Advanced Melanoma
Laval University

Active, not recruiting

Salmon Peptide Fraction: Safety and Cardiometabolic Health (SPF1)

Metabolic Syndrome

Canada
Erasmus Medical Center

Recruiting

Real-time Pressure Volume Loop Monitoring as a Guide for Enhanced Understanding of Changes in Elemental Cardiovascular Physiology During Therapeutic Strategies Aiming for Hemodynamic Optimization. Cohort II: Structural Heart Interventions (PLUTO-II) (PLUTO-II)

Heart Failure | Aortic Stenosis | Valvular Heart Disease | Mitral Insufficiency | Tricuspid Insufficiency

Netherlands
Provectus Biopharmaceuticals, Inc.

No longer available

Expanded Access Protocol for PV-10 for Cutaneous or Subcutaneous Tumors

Cutaneous or Subcutaneous Tumors Where There is no Comparable or Satisfactory | Approved Alternative Therapy

United States, Australia
Provectus Pharmaceuticals

Completed

PV-10 Chemoablation of Recurrent Breast Carcinoma

Breast Cancer

New Zealand
Provectus Pharmaceuticals

Completed

Intralesional PV-10 Chemoablation of Metastatic Melanoma

Melanoma

Australia
Exelixis

Terminated

A Phase 1 Study of XL019 in Adults With Polycythemia Vera

Polycythemia Vera

United States
Protagonist Therapeutics, Inc.

Recruiting

A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera (VERIFY)

Polycythemia Vera

United States, Hong Kong, Israel, Canada, Spain, Australia, Austria, Germany, United Kingdom, Hungary, Netherlands, Czechia, Portugal, Italy, Poland, France, Belgium, Chile, Turkey, Mexico
Incyte Corporation

Completed

Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study

Polycythemia Vera

United States, Belgium, Germany, Spain, Italy, United Kingdom, Ireland
corlife
University of Zurich; Universitaire Ziekenhuizen KU Leuven; Hannover Medical... and other collaborators

Completed

European Clinical Study for the Application of Regenerative Heart Valves - ESPOIR (ESPOIR)

Heart Valve Disease

Germany, Belgium, Netherlands, France, Italy, Moldova, Republic of, Switzerland, United Kingdom

Search clinical trials for: Post-polycythemia vera myelofbrosis (Post PV-PMF)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Equatorial Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations